VCNDD

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia. Read More

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read More